Influenza Vaccine Production
Annual vaccination is an effective method to prevent influenza infection. However, expanding the use of influenza vaccines in the Asia-pacific region faces many challenges. Timely production and deployment of influenza vaccines against seasonal and potential pandemic influenza viruses is required in non-vaccine producing countries (many of these still exist in Asia-pacific). In this whitepaper, we focus on the rapid development of influenza vaccine with the goal of generating a perfect bioprocessing solution that can speed up manufacturing process as an alternative to chicken eggs production.
Esco Aster, an independent contract development and manufacturing organisation (CDMO) headquartered in Singapore focus on highquality biomanufacturing of vaccines, biologics, and cell-therapy products, has a full-range of services and we partner global clients from early-stage discovery to market approvals of products.
To enable our primary vision to help non-vaccine producing countries to be self-sufficient in manufacturing, storing and distribution of vaccines, we recently partnered with biotech company Nuvonis (Austria) to establish efficient bioprocessing workflows that would enable the generation of influenza virus using Nuvonis serum-free Vero cell banks. The Nuvonis Vero cells originated from WHO cells and were adapted to serum-free/ animal component free growth. A Nuvonis working cell bank was used to demonstrate that Esco Vaccixcell CelCradle-500AP can be used to produce high cell densities under serum free condition, without the need of lengthy optimisation.